5-Amino-1MQ
compound
NNMT Inhibitor. Small molecule NNMT (nicotinamide N-methyltransferase) inhibitor. Blocks NNMT to elevate NAD+ and SAM, improve mitochondrial function, and reduce fat cell activity. Metabolic health, fat loss, NAD+ elevation.
Updated 7/14/2026
Acarbose
compound
T2D medication with longevity properties. ITP study showed 20% lifespan extension in male mice. Modulates gut microbiome, increases GLP-1, reduces glycemic variability. Brand names: Precose, Glucobay.
Updated 7/14/2026
BAM15
compound
Novel mitochondrial protonophore uncoupler. Reverses diet-induced obesity in mice without affecting food intake or lean mass. More potent and selective than DNP.
Updated 7/14/2026
Low-Dose Naltrexone (LDN)
compound
At low doses (1.5-4.5mg), intermittently blocks opioid receptors causing upregulation. Anti-inflammatory, immune modulating, neuroprotective. Off-label for autoimmune, fibromyalgia, cancer.
Updated 7/14/2026
Niagen (Nicotinamide Riboside)
compound
NAD+ precursor that converts to NMN then NAD+. Clinically shown to increase NAD+ levels by ~60% in humans. Reduces arterial stiffness, neuroprotective. Brand name: Tru Niagen.
Updated 7/14/2026
NR
compound
NAD+ precursor that converts to NMN then NAD+. Clinically shown to increase NAD+ levels by ~60% in humans. Reduces arterial stiffness, neuroprotective. Brand name: Tru Niagen.
Updated 7/14/2026
SLU-PP-332
compound
Orally bioavailable REV-ERB agonist. Regulates circadian rhythm, metabolic function, fat oxidation, and muscle endurance. Studied as exercise mimetic.
Updated 7/14/2026
Tesofensine
compound
Triple monoamine reuptake inhibitor (SNDRI). Originally developed for Parkinsons/Alzheimers. Significant appetite suppression and weight loss in trials (10.6% weight loss at 0.5mg/day).
Updated 7/14/2026